Herceptin With Dose-Dense Chemo Reduces Risk of Heart Problems

Save as Favorite
Sign in to receive recommendations (Learn more)

A study found that when Herceptin (chemical name: trastuzumab) was given in combination with dose-dense chemotherapy, the risk of heart problems from Herceptin was lower than when Herceptin was given with a routine schedule of chemotherapy.

Dose-dense chemotherapy means that the chemotherapy medicines are given every 2 weeks, instead of the routine schedule of every 3 weeks. Herceptin is a targeted therapy used to treat HER2-positive breast cancers. HER2-positive cancers have extra HER2 genes and make too many HER2 protein receptors (also called HER2/neu proteins). Herceptin works by blocking the HER2 protein on the cancer cell's surface.

Because it's harder on the body, the researchers were concerned that dose-dense chemotherapy might actually increase the risk of heart problems from giving Herceptin at the same time. They were pleased to find that this wasn't the case.

Only 1 woman out of 70 in this study (1.4%) had heart failure after getting Herceptin and dose-dense chemotherapy. When Herceptin is given with a routine schedule of chemotherapy, there is a 4% risk of heart problems.

Dose-dense chemotherapy is a relatively new, more intensive way to give chemotherapy. Doctors may recommend a dose-dense schedule for some women because other research has shown that this approach can improve survival and decrease the risk of recurrence more effectively than a routine chemotherapy schedule.

Dose-dense chemotherapy doesn't allow as much time for the immune system and red blood cells to recover between chemotherapy doses. Doctors sometimes use the medicines Neupogen (chemical name: filgrastim) or Neulasta (chemical name: pegfilgrastim) to strengthen the immune system, and Procrit (chemical name: epoetin alfa), Epogen (chemical name: epoetin alfa), or Aranesp (chemical name: darbepoetin alfa) to strengthen the red blood cell system during dose-dense chemotherapy.

If you've been diagnosed with HER2-positive early-stage breast cancer, your doctor will probably consider treating you with both Herceptin and chemotherapy after surgery to lower the risk of the cancer coming back. This study suggests that dose-dense chemotherapy won't increase your risk of heart problems from Herceptin. Together, you and your doctor can decide on a treatment plan that's best for you and your unique medical and personal situation.

Visit the breastcancer.org Targeted Therapies section to learn more about Herceptin and other targeted therapies used to treat breast cancer.

Was this article helpful? Yes / No

Springappeal17 miniad 1
Back to Top